Payment overview · 2025
General Payments
$572.06
14 reported records · 10 companies
Healthcare provider profile · identity verified
Richa Srivastava, M.D
Allopathic & Osteopathic Physicians|Internal Medicine · SCHAUMBURG, IL · NPI 1447351192
Verified facts
What the public records show
CMS Open Payments records show Richa Srivastava, M.D received $572.06 in general payments during 2025 across 14 reported records.
Smith+Nephew, Inc. accounted for 30.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 289 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 447 claims for Eliquis by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $173.04 | 30.2% | 3 | 2025 |
| Surgenex LLC | Unresolved — no canonical attribution shown | $157.34 | 27.5% | 1 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $89.99 | 15.7% | 3 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $28.53 | 5.0% | 1 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $25.13 | 4.4% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $24.34 | 4.2% | 1 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $21.04 | 3.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.76 | 3.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.63 | 3.1% | 1 | 2025 |
| Melinta Therapeutics, LLC | Unresolved — no canonical attribution shown | $16.26 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $572.06 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ArdeoGraft Normalized: ardeograft |
Biological | Surgenex LLC | $157.34 | 1 | 2025 |
Source payment records
|
|||||
| PelloGraft Normalized: pellograft |
Biological | Surgenex LLC | $157.34 | 1 | 2025 |
Source payment records
|
|||||
| RenoGraft Normalized: renograft |
Biological | Surgenex LLC | $157.34 | 1 | 2025 |
Source payment records
|
|||||
| SurGraft Normalized: surgraft |
Biological | Surgenex LLC | $157.34 | 1 | 2025 |
Source payment records
|
|||||
| SurMatrix Normalized: surmatrix |
Biological | Surgenex LLC | $157.34 | 1 | 2025 |
Source payment records
|
|||||
| GRAFIX PL Normalized: grafix pl |
Biological | Smith+Nephew, Inc. | $149.98 | 1 | 2025 |
Source payment records
|
|||||
| OASIS Normalized: oasis |
Device | Smith+Nephew, Inc. | $149.98 | 1 | 2025 |
Source payment records
|
|||||
| STRAVIX PL Normalized: stravix pl |
Biological | Smith+Nephew, Inc. | $149.98 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $89.99 | 3 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $89.99 | 3 | 2025 |
Source payment records
|
|||||
| AFFINITY Normalized: affinity |
Medical Supply | Organogenesis Inc. | $25.13 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $24.34 | 1 | 2025 |
Source payment records
|
|||||
| ALLEVYN LIFE L 15.4X15.4 CTN10 Normalized: allevyn life l 15 4x15 4 ctn10 |
Device | Smith+Nephew, Inc. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $18.76 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| Kimyrsa Normalized: kimyrsa |
Drug | Melinta Therapeutics, LLC | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| Orbactiv Normalized: orbactiv |
Drug | Melinta Therapeutics, LLC | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $3.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
289 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
38 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
447 | 34 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1251 | 162 |
| Levothyroxine Sodium | Levothyroxine Sodium | 559 | 80 |
| Potassium Chloride | Potassium Chloride | 504 | 54 |
| Mirtazapine | Mirtazapine | 475 | 40 |
| Furosemide | Furosemide | 469 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 460 | 74 |
| Eliquis | Apixaban | 447 | 34 |
| Gabapentin | Gabapentin | 440 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 406 | 64 |
| Omeprazole | Omeprazole | 380 | 49 |
| Losartan Potassium | Losartan Potassium | 374 | 65 |
| Donepezil Hcl | Donepezil Hcl | 333 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 321 | 43 |
| Lisinopril | Lisinopril | 294 | 47 |
| Jardiance | Empagliflozin | 289 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 281 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 259 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 251 | 44 |
| Famotidine | Famotidine | 247 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 240 | 28 |
| Sertraline Hcl | Sertraline Hcl | 230 | 28 |
| Memantine Hcl | Memantine Hcl | 215 | 21 |
| Metformin Hcl | Metformin Hcl | 215 | 43 |
| Xarelto | Rivaroxaban | 211 | 18 |
| Carvedilol | Carvedilol | 209 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 186 | 32 |
| Heparin Sodium | Heparin Sodium,porcine | 181 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 176 | 53 |
| Trazodone Hcl | Trazodone Hcl | 171 | 13 |
| Warfarin Sodium | Warfarin Sodium | 153 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 141 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 136 | 25 |
| Allopurinol | Allopurinol | 131 | 18 |
| Alendronate Sodium | Alendronate Sodium | 127 | 26 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 127 | 41 |
| Simvastatin | Simvastatin | 127 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 126 | 12 |
| Risperidone | Risperidone | 126 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 119 | 12 |
| Baclofen | Baclofen | 116 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 107 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 105 | 26 |
| Januvia | Sitagliptin Phosphate | 104 | 11 |
| Sodium Chloride | 0.9 % Sodium Chloride | 103 | 17 |
| Prednisone | Prednisone | 101 | 25 |
| Finasteride | Finasteride | 97 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 94 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 90 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 88 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 85 | 27 |
| Latanoprost | Latanoprost | 85 | suppressed |
| Spironolactone | Spironolactone | 85 | 14 |
| Bumetanide | Bumetanide | 84 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 35 |
| Cephalexin | Cephalexin | 80 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 19 |
| Midodrine Hcl | Midodrine Hcl | 73 | 16 |
| Levetiracetam | Levetiracetam | 72 | suppressed |
| Myrbetriq | Mirabegron | 68 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 67 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 66 | suppressed |
| Clonazepam | Clonazepam | 63 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 58 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 58 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 56 | suppressed |
| Chlorthalidone | Chlorthalidone | 56 | suppressed |
| Enulose | Lactulose | 56 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 56 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 53 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 51 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 51 | suppressed |
| Alprazolam | Alprazolam | 50 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 50 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 48 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 48 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 46 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 46 | suppressed |
| Lovastatin | Lovastatin | 46 | suppressed |
| Nystatin | Nystatin | 45 | 22 |
| Olanzapine | Olanzapine | 43 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 34 |
| Enoxaparin Sodium | Enoxaparin Sodium | 42 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 41 | suppressed |
| Lorazepam | Lorazepam | 40 | 13 |
| Farxiga | Dapagliflozin Propanediol | 39 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 38 | 38 |
| Cefuroxime | Cefuroxime Axetil | 38 | 28 |
| Gemfibrozil | Gemfibrozil | 38 | suppressed |
| Lactulose | Lactulose | 38 | suppressed |
| Ozempic | Semaglutide | 38 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | 20 |
| Montelukast Sodium | Montelukast Sodium | 37 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 36 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 35 | suppressed |
| Atenolol | Atenolol | 34 | suppressed |
| Budesonide | Budesonide | 34 | suppressed |
| Irbesartan | Irbesartan | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 33 | suppressed |
| Azithromycin | Azithromycin | 32 | 29 |
| Incruse Ellipta | Umeclidinium Bromide | 32 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 32 | suppressed |
| Austedo | Deutetrabenazine | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 24 |
| Temazepam | Temazepam | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 17 |
| Bicalutamide | Bicalutamide | 30 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 29 | suppressed |
| Erythromycin | Erythromycin Base | 29 | 13 |
| Fluconazole | Fluconazole | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Nyamyc | Nystatin | 29 | 13 |
| Topiramate | Topiramate | 29 | suppressed |
| Carbamazepine | Carbamazepine | 28 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 28 | suppressed |
| Primidone | Primidone | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 27 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Anastrozole | Anastrozole | 26 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 26 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 24 | 16 |
| Digoxin | Digoxin | 24 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 24 | 22 |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 15 |
| Timolol Maleate | Timolol Maleate | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 22 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 16 |
| Methimazole | Methimazole | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 22 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 21 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 21 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Meropenem | Meropenem | 20 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 20 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Hydroxyurea | Hydroxyurea | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Haloperidol | Haloperidol | 16 | suppressed |
| Humalog | Insulin Lispro | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 12 |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Prilosec | Omeprazole Magnesium | 13 | suppressed |
| Restasis | Cyclosporine | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Ofloxacin | Ofloxacin | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $572.06 · 14 records | Smith+Nephew, Inc. | AFFINITY, ALLEVYN LIFE L 15.4X15.4 CTN10, AUSTEDO XR, ArdeoGraft, COLLAGENASE SANTYL, GRAFIX PL, KISUNLA, Kerecis GraftGuide, Kerecis SurgiClose, Kimyrsa, NURTEC ODT, OASIS, Orbactiv, PAXLOVID, PelloGraft, RenoGraft, STRAVIX PL, SurGraft, SurMatrix | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error